
Opinion|Videos|May 2, 2025
Translating OS Data Into Patient Conversations: Balancing Benefit and Burden
Panelists discuss how explaining survival benefits to patients must be tailored to individual goals and expectations, with many patients having specific life milestones they hope to reach.
Advertisement
Episodes in this series

Communicating Survival Benefits and Treatment Trade-Offs
Main Discussion Topics:
- Strategies for explaining survival benefits to patients
- Incorporating patient goals into treatment discussions
- Avoiding preconceived notions about patient preferences based on age or other factors
Key Points for Physicians:
- Focus on patient-specific goals (eg, attending important life events) when discussing treatments
- Recognize that patient preferences don’t always align with physician assumptions
- Consider results from patient surveys that reveal preferences for quality of life over extended therapy
Notable Insights:
Data from a Chinese survey showed that over 70% of patients, family members, and doctors would prefer osimertinib monotherapy over combination therapy despite a 9-month delay in recurrence with the latter.
Clinical Significance:
Effective shared decision-making requires understanding individual patient goals and preferences rather than making assumptions based on demographic factors or physician biases.
Advertisement
Related to this article

The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.

A European Commission decision on belzutifan plus lenvatinib in pretreated advanced ccRCC is expected within 2 months, based on LITESPARK-011 data.

The phase 3 4WARD trial is evaluating mavorixafor for reducing infection rates and raising neutrophil counts in patients with primary chronic neutropenia.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Age, geographic location, transportation barriers, and language and communication barriers may limit patient opportunities to participate in research.

Targeting two alternate pathways at the same time led to improved outcomes in multiple preclinical models of advanced breast cancer.

Updated LEGEND cohort 1 data showed a 56% CR rate and a 24% 12-month CR rate with detalimogene in BCG-unresponsive, high-risk NMIBC with CIS.
Advertisement
Advertisement
Trending on OncLive
1
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
2
Dr Levy on Where Iza-Bren May Fit Following Osimertinib In EGFR-Mutated NSCLC
3
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
4
Dr Levy on How the EGFR-Targeted Therapy Landscape Has Evolved in NSCLC
5

